Research Papers:
Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer
Metrics: PDF 2322 views | HTML 3122 views | ?
Abstract
Shanshan Wu1,2,*, Xiangfei Zhao2,*, Sudong Wu2, Rui Du2, Qi Zhu2, Henghu Fang2, Xinhong Zhang2, Chunyang Zhang2, Wei Zheng2, Jihua Yang2, Huasong Feng2
1Postgraduate Team, Chinese PLA General Hospital, Beijing 100853, China
2Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China
*These authors have contributed equally to this work
Correspondence to:
Huasong Feng, email: [email protected]
Keywords: meta-analysis, B7-H3, prognosis, lung cancer, clinical
Received: September 08, 2016 Accepted: October 19, 2016 Published: November 07, 2016
ABSTRACT
Previous studies have investigated the prognostic significance of B7 homolog 3 (B7-H3) in non-small cell lung cancer (NSCLC), however, the results remain controversial. This study was aimed to determine the correlation between B7-H3 and survival as well as clnicalpathological characteristics in NSCLC using meta-analysis. We searched the electronic databases of PubMed, Embase, Web of Science, and China National Knowledge Infrastructure (CNKI) for relevant studies up to October 9, 2016. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to estimate the impact of B7-H3 on overall survival (OS). Combined odds ratios (ORs) and 95%CIs were utilized to evaluate the correlations between B7-H3 and clinicalpathological features. This meta-analysis finally included 7 studies with 864 patients. The results showed that B7-H3 had no significant association with OS (HR=0.88, 95%CI: 0.36-2.13, p=0.776). High B7-H3 expression was a significant indicator of lymph node metastasis (OR=3.92, 95%CI: 2.65-5.81, p<0.001), and advanced TNM stage (OR=3.53, 95%CI: 2.45-5.09, p<0.001). B7-H3 has the potential to serve as a marker of tumor aggressiveness and lymph node metastasis in NSCLC. However, due to several limitations, further large-scale studies are needed to validate our results.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13177